BOSTON--(BUSINESS WIRE) — T.Rx Capital, a new venture capital firm focused on early-stage healthcare innovation, today announced the close of its inaugural fund, T.Rx Capital Fund I, at $77.5 million. The fund is dedicated to backing visionary founders building at the intersection of technology and biology including biotechnology, techbio, and tech-enabled services.

Fund I attracted strong backing from a global base of investors, including institutional allocators, family offices, and high-net-worth individuals across North America, Europe, the Middle East, and Asia. In addition, the firm had backers that include individual founders from Polaris Partners, Lux Capital, Third Rock Ventures, ARCH Venture Partners, and Dr. Robert Langer, who also serves as Executive Chairman of T.Rx Capital.

Co-founded by Michael Langer, Dr. Corey McCann, and Dr. Kwesi Frimpong-Boateng, T.Rx Capital has a team of seasoned healthcare investors and operators with backgrounds creating, funding, scaling, and transacting healthcare companies.

“We launched T.Rx Capital to identify and back the next generation of category-defining healthcare companies,” said Michael Langer. “As biology and technology converge, we see a historic opportunity to build scalable platforms that can fundamentally reshape disease treatment. We partner early with scientifically rigorous, execution-focused teams and provide the capital, network, and strategic support to help them build durable value from day one.”

T.Rx Capital is supported by seasoned Venture Partners Dr. Debbie Lin, Vice President of Strategic Partnerships in Precision Oncology at Caris Life Sciences, and Dr. Liz Kwo, Chief Commercial Officer at Everly Health.

The firm is further strengthened by a distinguished advisory board, composed of world-renowned leaders in science, medicine, and industry. This includes:

• Dr. Robert Langer – Institute Professor at MIT and co-founder of more than 40 biotech companies including Moderna
• Mark Levin – founder of Third Rock Ventures and of more than 30 biotech companies
• Dr. Freda Lewis-Hall – former Chief Medical Officer and Chief Patient Officer at Pfizer
• John Abele – co-founder and former co-Chairman of Boston Scientific
• Dr. Al Sandrock – CEO of Voyager Therapeutics and former Head of Research & Development at Biogen
• Peter Barton Hutt – former Chief Counsel of the US Food and Drug Administration, Senior Counsel at Covington & Burling LLP

This collective leadership brings significant depth of experience and a proven track record of company-building, scientific excellence, and industry impact, positioning T.Rx Capital to support transformative innovation from inception through exit.

T.Rx Capital Fund I targets early-stage investments across healthcare, with a focus on company creation through Series B. The firm aims to build a concentrated portfolio of 10–15 companies, writing $5–$10 million checks and taking active roles in company creation, scale, and governance.

“2025 presents a unique window for biotech investment,” said Dr. Frimpong-Boateng. “After a reset in valuations and renewed capital discipline, we’re seeing breakthrough science accelerate alongside growing pharma demand for external innovation. With exit markets recovering, this is an exceptional time for venture capital to support the next wave of transformative biotech companies.”

About T.Rx Capital

T.Rx Capital is a Boston and San Francisco-based venture capital firm investing in healthcare companies at the intersection of biology and technology. The firm brings together deep investing and operating expertise to help founders build breakthrough companies in healthcare. With a hands-on, long-term approach, T.Rx Capital partners with mission-driven teams from inception through scale.

Media Contact

‍T.Rx Capital
Email: kimberly.ha@kkhadvisors.com